@the_news_21
Glenmark on Wednesday launched its Nitric Oxide Nasal Spray under the brand name FabiSpray in India.
Glenmark Pharmaceuticals Limited (Glenmark) and Canadian pharmaceutical company SaNOtize Research & Development Corp. launched the Nitric Oxide Nasal Spray for treatment of adult patients suffering from COVID-19.
The company received manufacturing-marketing approval from India’s drug regulator Drugs Controller General of India (DCGI) for Nitric Oxide Nasal Spray as part of accelerated approval process.
“Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 per cent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in COVID-19 patients. Glenmark to market NONS under the brand name FabiSpray,” reads the official statement.
